Histogen Inc.: Nasdaq/NYSE listing notice — Histogen receives Nasdaq deficiency notice for minimum bid price non-compliance

Histogen Inc.

Nasdaq letter on June 5, 2023 citing bid price below $1.00 for 30 consecutive business days.
Compliance period of 180 days until December 4, 2023 to regain $1.00 minimum closing bid for 10 days.
If not cured, may request additional 180 days if meets all other Nasdaq listing standards.
Stock continues trading on Nasdaq Capital Market under symbol HSTO during cure period.
No assurance of regaining compliance; delisting risk remains.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 1.0

Histogen Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

June 5, 2023, Histogen Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between April 21, 2023, through June 2, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until De

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-026352

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.